Science AI Journal
Medicine · Research topic

Open research questions in Brain Metastases and Treatment

50 unresolved questions extracted from the limitations and future-work sections of 118 Brain Metastases and Treatment papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Diagnostic challenge due to rarity of TTM. Need for integrated surgical, pathological, and molecularly guided multidisciplinary decision-making. Management of widespread metastatic disease.

    Synchronous tumor-to-tumor metastasis of breast carcinoma to intracranial meningioma: illustrative case · 2026 · DOI

  • Further study of the mechanisms of TTM. Investigation of the optimal treatment strategies for TTM.

    Synchronous tumor-to-tumor metastasis of breast carcinoma to intracranial meningioma: illustrative case · 2026 · DOI

  • Most available evidence remains retrospective, single-center, and heterogeneous in methodology. The limited number of prospective or matched analyses limits causal inference and precludes robust quantitative comparison across IT regimens and delivery routes.

    Advances in Ommaya reservoir–based intrathecal therapy for leptomeningeal metastasis from non–small cell lung cancer: a systematic review · 2026 · DOI

  • Further studies are needed to establish the efficacy and safety of intrathecal therapy in NSCLC-related leptomeningeal metastasis. Research should focus on the development of more effective and targeted therapies for this condition.

    Advances in Ommaya reservoir–based intrathecal therapy for leptomeningeal metastasis from non–small cell lung cancer: a systematic review · 2026 · DOI

  • Further studies are needed to fully explore the clinical potential of RET inhibition in ER+BC. Investigation of the role of GDNF-RET signaling in other types of cancer is warranted.

    RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis · 2026 · DOI

  • The underlying mechanisms of brain metastasis in ER+BC are poorly understood. Specific drivers of brain metastasis from ER+BC remain poorly characterized.

    RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis · 2026 · DOI

  • Brain metastases have poor prognosis and limited quality of life. Standard treatments have limited effectiveness. Biological heterogeneity may bias pooled estimates.

    Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis · 2026 · DOI

  • Further research is needed to fully establish the effectiveness of WBRT-SIB. Randomized trials comparing WBRT-SIB to WBRT alone are needed. Studies should consider biological heterogeneity in pooled estimates.

    Whole-brain radiotherapy with simultaneous integrated boost in treatment of patients with brain metastases: a systematic review and meta-analysis · 2026 · DOI

  • The clinical, histopathological, and molecular heterogeneity among patients with brain metastases necessitates individualized treatment decisions. The lack of standardized prognostic indices for patients with brain metastases treated with cranial radiotherapy. The need for accurate prediction of overall survival to guide treatment decisions.

    Comparative validation of prognostic indices in brain metastases receiving cranial radiotherapy · 2026 · DOI

  • Diagnostic challenges of brain metastases from rare tumors. Poor clinical outcomes associated with brain metastases. Limited understanding of brain metastases from rare tumors.

    Brain rare metastatic tumors: a clinicopathological analysis of 14 cases · 2026 · DOI

  • The brain tumor microenvironment is distinct from primary lung tumors and is characterized by reduced lymphocyte infiltration and enrichment of immunosuppressive myeloid populations. The development of brain metastases is a complex process involving multiple steps and interactions between tumor cells and the brain tumor microenvironment. Therapeutic strategies for brain metastases in non-small cell lung cancer are limited and often ineffective.

    The Tumor Microenvironment in Non-Small Cell Lung Cancer Brain Metastases: Composition, Dynamics, and Therapeutic Implications · 2026 · DOI

  • Further studies are needed to elucidate the mechanisms of brain metastasis and the role of the brain tumor microenvironment in metastatic progression and therapeutic resistance. Research should focus on identifying potential therapeutic targets, including the tumor vasculature and immunosuppressive myeloid populations.

    The Tumor Microenvironment in Non-Small Cell Lung Cancer Brain Metastases: Composition, Dynamics, and Therapeutic Implications · 2026 · DOI

  • Future trials must include CNS-specific endpoints, incorporate liquid biopsy and imaging biomarkers, and emphasize preservation of neurocognitive function alongside survival.

    Breast cancer brain metastasis: from molecular insights to therapeutic innovation · 2026 · DOI

  • The previously observed NCF benefit of SRT over WBRT (+/- HA) is better characterized as a delay in NCF decline—both modalities lead to deterioration from baseline over time (2, 3, 31). Emerging evidence indicates that NCF depends not only on the hippocampus but also on the integrity of key white matter tracts (WMT) that subserve memory, language, executive function, and other cognitive domains (62, 63). This raises the possibility that combining SRT’s dose−painting precision with brain connectomics could further optimize NCF preservation (64). Brain connectomics refers to the complete set of structural and functional connections within the brain (common networks include the default mode, central executive, salience, dorsal attention, and ventral attention networks). It spans from microscopic axonal connections to macroscopic white matter fiber bundles, the latter being the primary focus in current clinical neuroscience (65, 66). Structural connectivity is typically reconstructed using diffusion MRI and tractography, mapping physical connections between brain regions; functional connectomics relies on resting−state or task −based fMRI to capture cooperative activity across regions (67, 68). Integrating connectomics into SRT planning may help to deliberately avoid or constrain dose to eloquent white matter bundles, thereby refining treatment plans–an approach that has been reported in benign intracranial diseases (62). In the brain metastasis setting, a single−institution prospective study (reported as a conference abstract in the Red Journal) evaluated this strategy in 84 patients (77 with brain metastases, 182 lesions) (69). Using connectomics to identify 23 key WMT and the hippocampi, dose constraints were applied during SRT planning(single fraction WMTDmax =12Gy, hippocampiDmax=8.4Gy). With a median follow−up of 28 months, the 12−month local control rate was 98%, and no significant imaging−detected injury to the selected white matter tracts was observed. The mean cognitive impairment rate remained stable (26% at baseline vs 25% at 3 months post −SRT), and mean T−scores for cognitive performance and quality of life showed no significant decline (all P>0.1). Importantly, unlike previous studies that reported progressive decline (31), tests of verbal fluency and word retrieval even improved (P = 0.02 and P = 0.01, respectively). This promising and attractive combination strategy is currently being evaluated in multiple clinical trials (NCT04343157, NCT04073966). 2.4 Dose and fractionation optimization in stereotactic radiotherapy 2.4.1 SRS and FSRT SRS has extensive clinical experience in treating small lesions.The International Stereotactic Radiosurgery Society (ISRS) considers metastases smaller than 1 cm in diameter suitable for safe treatment with Gamma Knife, CyberKnife, or linear accelerator (Linac)-based SRS (70).

    Stereotactic radiotherapy for brain metastases: indications, dose fractionation, technological innovations, and evolving combination strategies – a comprehensive review · 2026 · DOI

  • Abstract Background Cesium-131 collagen tile has gained traction as an intraoperative brachytherapy platform for recurrent intracranial tumors, but outcome data in newly diagnosed brain metastases (nBM) remain sparse, with fewer than ten cases reported.

    Intraoperative, Interstitial Brachytherapy in Newly Diagnosed Brain Metastases Through Cesium-131 Collagen Tile Implant: A Multi-Institutional Case Series · 2026 · DOI

  • There is a need for external validation of prognostic indices in patients with brain metastases treated with cranial radiotherapy. There is a need to evaluate the combined prognostic impact of clinical variables and treatment-related factors on overall survival.

    Comparative validation of prognostic indices in brain metastases receiving cranial radiotherapy · 2026 · DOI

  • While current guidelines recommend the analysis of established cancer driver genes in BM tissue, little is known about its real‐life implementation and relevance on oncological treatment strategies.

    Clinical Implementation and Oncological Relevance of Molecular Profiling in Brain Metastases Patients—A Multicenter Retrospective Cohort Study · 2026 · DOI

  • There is a limited regional literature on the MRI characteristics of brain metastases in Iraqi patients. The study aims to provide valuable information regarding the MRI characteristics of brain metastases in this population.

    MAGNETIC RESONANCE IMAGING CHARACTERISTICS OF BRAIN METASTASES IN PATIENTS WITH MALIGNANCY AT AL-THAQALAYN ONCOLOGY HOSPITAL, BASRA, IRAQ · 2026 · DOI

  • The study is limited by its small sample size. The study only evaluates the short-term effects of high-dose corticosteroid therapy. The study does not compare the effectiveness of high-dose corticosteroid therapy to other treatment options.

    Stop LCNP: High dose corticosteroid therapy for late radiation-associated lower cranial neuropathy: A report of the phase I dose finding trial and parallel prospective data registry · 2026 · DOI

  • There are no proven therapies to reverse radiation-associated lower cranial neuropathy. Current treatment options are limited, and there is a need for effective treatments to mitigate the effects of radiation-associated lower cranial neuropathy.

    Stop LCNP: High dose corticosteroid therapy for late radiation-associated lower cranial neuropathy: A report of the phase I dose finding trial and parallel prospective data registry · 2026 · DOI

  • The case presents a single patient's experience and may not be generalizable. The role of COVID-19 vaccination in the development of radiation necrosis is unclear.

    Late radiation necrosis following stereotactic radiosurgery after COVID-19 vaccination: a case report and hypothesis of immune-mediated inflammatory activation · 2026 · DOI

  • Late radiation necrosis occurring several years after SRS remains uncommon and incompletely characterized. The role of COVID-19 vaccination in the development of radiation necrosis is unclear.

    Late radiation necrosis following stereotactic radiosurgery after COVID-19 vaccination: a case report and hypothesis of immune-mediated inflammatory activation · 2026 · DOI

  • Future studies should investigate the long-term cognitive function and quality of life outcomes of SRT+ICIs and HA-WBRT+ICIs. Future studies should explore the efficacy of SRT+ICIs in other patient populations, such as those with breast cancer or melanoma. Future studies should investigate the potential prognostic factors associated with overall survival and intracranial progression-free survival.

    Stereotactic versus hippocampal avoidance whole-brain radiotherapy combined with immune checkpoint inhibitors for multiple brain metastases in non-small cell lung cancer: a multi-center retrospective study · 2026 · DOI

  • Further studies are needed to confirm the efficacy of 22 Gy SRS in achieving local control of brain metastases. Studies should investigate the long-term outcomes of SRS for brain metastases. Research should focus on optimizing SRS dosing strategies to minimize the risk of radiation necrosis.

    Impact of stereotactic radiosurgery dose on local control and radiation necrosis in metastatic brain lesions: a comparative study · 2026 · DOI

  • The optimal dosing strategies for SRS in the treatment of brain metastases remain unclear. The balance between achieving adequate local control and minimizing the risk of radiation necrosis is complex.

    Impact of stereotactic radiosurgery dose on local control and radiation necrosis in metastatic brain lesions: a comparative study · 2026 · DOI

Most-cited papers in Brain Metastases and Treatment

Most recent work

Find a gap in your own Brain Metastases and Treatment sub-topic

This page shows what the Brain Metastases and Treatment literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
50 open questions have been extracted from the limitations and future-work passages of 118 Brain Metastases and Treatment papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.